1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 14,000 | 14,200 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | Pharming Group N.V.: Pharming Group to report first quarter 2026 financial results and provide business update on May 7 | 315 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial... ► Artikel lesen | |
| 16.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.04. | Pharming Group N.V.: Pharming Group announces the 2026 Annual General Meeting of Shareholders | 259 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company's 2026 Annual General Meeting... ► Artikel lesen | |
| 07.04. | Pharming Group N.V.: Pharming Group to participate in April investor conferences | 375 | GlobeNewswire (Europe) | Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences... ► Artikel lesen | |
| 02.04. | Pharming Group N.V. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.04. | Pharming Group N.V. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 02.04. | Pharming Group N.V.: Pharming Group announces the filing of its 2025 Annual Report and Form 20-F | 3 | GlobeNewswire (USA) | ||
| 27.03. | Pharming granted EU backing for rare immunodeficiency therapy | 2 | Seeking Alpha | ||
| PHARMING GROUP NV ADR Aktie jetzt für 0€ handeln | |||||
| 27.03. | Pharming Group N.V.: Pharming Group receives positive CHMP opinion for Joenja (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older | 1.059 | GlobeNewswire (Europe) | If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiencyDecision... ► Artikel lesen | |
| 24.03. | Pharming Group N.V. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.03. | Pharming Group N.V.: Pharming Group announces approval of Joenja (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older | 303 | GlobeNewswire (Europe) | First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients... ► Artikel lesen | |
| 12.03. | Pharming outlines $405M-$425M 2026 revenue target as Joenja and RUCONEST drive growth | 9 | Seeking Alpha | ||
| 12.03. | Wainwright bekräftigt "Kaufen"-Rating für Pharming-Aktie dank stabilem Wachstum | 6 | Investing.com Deutsch | ||
| 12.03. | Wainwright reiterates Pharming stock Buy rating on commercial growth | 2 | Investing.com | ||
| 12.03. | Pharming Group meldet Umsatz von 106,5 Mio. US-Dollar im 4. Quartal und bestätigt Prognose für 2026 | 14 | Investing.com Deutsch | ||
| 12.03. | Pharming beats top-line estimates; introduces FY26 outlook | 2 | Seeking Alpha | ||
| 12.03. | Pharming Group N.V. Bottom Line Climbs In Q4 | 1 | RTTNews | ||
| 12.03. | Pharming Group N.V.: Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow | 849 | GlobeNewswire (Europe) | Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST and rising demand for Joenja (leniolisib) Fourth quarter 2025 total revenues increased by 15%... ► Artikel lesen | |
| 03.03. | Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? | 2 | Zacks | ||
| 26.02. | Pharming Group N.V.: Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 | 1.004 | GlobeNewswire (Europe) | Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,540 | +0,52 % | Cathie Wood's ARK sells AMD stock, buys Roblox and Intellia | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,300 | -3,74 % | Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know | ||
| ATAIBECKLEY | 3,500 | -1,69 % | Psychedelika im Aufwind - AtaiBeckley und Emyria im Fokus | ||
| BIOMERIEUX | 69,65 | -1,90 % | BioMerieux Q1 Sales Down 3.9% On Organic Basis; Revises 2026 Guidance | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - BioMerieux (EYWN.MU, BIM.PA) reported first quarter consolidated sales of 984 million euros, down 10.4% as reported from last year. On an organic basis,... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,350 | -0,57 % | Lir Life Sciences Corp.: LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules | VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company) is pleased to announce, further to its news... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 1,000 | +2,71 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 26,000 | -1,52 % | Genus PLC - Total Voting Rights | ||
| ANAPTYSBIO | 53,64 | -4,18 % | Amended: GSK's Tesaro Provides Update On Anticipatory Breach Claim In AnaptysBio Litigation | LONDON (dpa-AFX) - GSK plc (GSK, GSK.L), subsidiary Tesaro, Inc. (TSRO), on Monday, said the Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc. (ANAB) against... ► Artikel lesen | |
| MEIRAGTX | 7,500 | -1,96 % | Here is Why MeiraGTx Holdings (MGTX) is One of the Best Growth Stocks Under $10 | ||
| ABIONYX PHARMA | 3,385 | -2,59 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 3,100 | +3,33 % | XTL BioPharmaceuticals to acquire Psyga Bio in all-stock deal; shares surge | ||
| AKESO | 14,765 | -2,44 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| MAAT PHARMA | 5,840 | +1,39 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
21.04.2026 / 15:09 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| NEUMORA THERAPEUTICS | 2,430 | -1,62 % | Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies KOASTAL-2 and -3 fully enrolled in the first quarter of... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,047 | -1,27 % | Isofol Medical AB: Isofol optimizes the design of its phase Ib/II study following new regulatory approval | GOTHENBURG, Sweden, April 15, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that the German regulatory authority BfArM has approved an optimized design for the company's... ► Artikel lesen |
Das Unternehmen PHARMING GROUP NV ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,74 % bei einem Aktienkurs von 13,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMING GROUP NV ADR finden Sie auf Wallstreet Online.